Spruce Biosciences Inc [SPRB] stock is trading at $0.72, up 1.33%. An important factor to consider is whether the stock is rising or falling in short-term value. The SPRB shares have gain 2.22% over the last week, with a monthly amount drifted -15.50%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Spruce Biosciences Inc [NASDAQ: SPRB] stock has seen the most recent analyst activity on March 14, 2024, when RBC Capital Mkts downgraded its rating to a Sector Perform and also revised its price target to $2 from $9. Previously, Leerink Partners downgraded its rating to Market Perform on March 14, 2024, and dropped its price target to $2. On March 14, 2024, downgrade downgraded it’s rating to Neutral. H.C. Wainwright downgraded its rating to a Neutral. Guggenheim downgraded its rating to a Neutral. Guggenheim started tracking with a Buy rating for this stock on February 21, 2024, and assigned it a price target of $10. In a note dated December 17, 2021, Oppenheimer initiated an Outperform rating and provided a target price of $15 on this stock.
Spruce Biosciences Inc [SPRB] stock has fluctuated between $0.67 and $5.95 over the past year. Spruce Biosciences Inc [NASDAQ: SPRB] shares were valued at $0.72 at the most recent close of the market.
Analyzing the SPRB fundamentals
Gross Profit Margin for this corporation currently stands at 0.98% with Operating Profit Margin at -5.15%, Pretax Profit Margin comes in at -4.75%, and Net Profit Margin reading is -4.72%. To continue investigating profitability, this company’s Return on Assets is posted at -0.46, Equity is -0.52 and Total Capital is -0.65. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.05.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 0.7014 points at the first support level, and at 0.6855 for the second support level. However, for the 1st resistance point, the stock is sitting at 0.7420, and for the 2nd resistance point, it is at 0.7667.
Spruce Biosciences Inc [SPRB] reported earnings per share of -$0.24 for its fiscal quarter that ended on 12/31/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.39/share, meaning a difference of $0.15 and a surprise factor of 38.50%. By comparison, the stated earnings for the previous quarter ended on 9/30/2023 were -$0.3 per share as compared to estimates of -$0.35 per share, a difference of $0.05 representing a surprise of 14.30%.
Ratios To Look Out For
For context, Spruce Biosciences Inc’s Current Ratio is 4.18. On the other hand, the Quick Ratio is 4.18, and the Cash Ratio is 3.94. Considering the valuation of this stock, the price to sales ratio is 2.93, the price to book ratio is 0.38.
Transactions by insiders
Recent insider trading involved Novo Holdings A/S, 10% Owner, that happened on Mar 21 ’24 when 0.47 million shares were sold. 10% Owner, Novo Holdings A/S completed a deal on Mar 20 ’24 to sell 0.36 million shares. Meanwhile, 10% Owner Novo Holdings A/S sold 0.59 million shares on Mar 19 ’24.
